



Monday, December 7, 2020

Oral Presentations at 2020 ASH Annual Meeting

Note: all times listed are Pacific Time

| Presentation | Speaker | Time/Channel |
|---|--|------------------------|
| <i>Education Program: Acute Myeloid Leukemia - So Many Treatment Options; How Do You Decide?</i> | Jacqueline S. Garcia, MD | 7:00 a.m., Channel 13 |
| Does Patient Fitness Play a Role in Determining First-Line Treatment for AML? | | |
| 531: Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma | Reid W. Merryman, MD | 7:15 a.m., Channel 7 |
| 520: Using an in-Vivo Degron-Based Approach to Interrogate Dependencies of Serially Acquired Mutations - Including DNMT3a-R882 and NPM1c - in Acute Myeloid Leukemia | Andrew A. Guirguis, MD, PhD | 7:30 a.m., Channel 14 |
| 521: Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis | Katsuhiko Togami, MD, PhD | 7:45 a.m., Channel 14 |
| 569: Targeting Oncoproteins with a Positive Selection Assay for Protein Degradation | Sagar Koduri, MD, PhD | 8:00 a.m., Channel 5 |
| 604: Exploring POU2AF1 (BOB-1) Dependency and Transcription Addiction in Multiple Myeloma | Zuzana Chyra, PhD | 9:30 a.m., Channel 11 |
| 611: Engineered Memory-like NK Cells Targeting a Neoepitope Derived from Intracellular NPM1c Exhibit Potent Activity and Specificity Against Acute Myeloid Leukemia | Han Dong, PhD | 9:45 a.m., Channel 21 |
| 606: Atpase Family AAA Domain-Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma | Lakshmi B. Potluri, MBBS | 10:00 a.m., Channel 11 |
| 586: Pegaspargase Re-Challenge after Grade 2 Hypersensitivity Reaction in Childhood Acute Lymphoblastic Leukemia: Results from DFCI 16-001 | Lynda M. Vrooman, MD, Dana-Farber/Boston Children's | 10:00 a.m., Channel 13 |



Monday, December 7, 2020

Oral Presentations at 2020 ASH Annual Meeting

Note: all times listed are Pacific Time

| Presentation | Speaker | Time/Channel |
|--|---|------------------------|
| 613: Development of a Novel MICA/B-Specific CAR As a Pan-Tumor Targeting Strategy for Off-the-Shelf, Cell-Based Cancer Immunotherapy | Kai W. Wucherpfennig, MD, PhD | 10:15 a.m., Channel 21 |
| 587: Orthopedic Toxicity Among Adolescents and Young Adults Treated on DFCI ALL Consortium Trials | Yannis K. Valtis, MD, Brigham and Women's Hospital | 10:15 a.m., Channel 13 |
| 665: Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application | Annamaria Gulla, MD | 11:30 a.m., Channel 11 |
| 659: Multiplexed CRISPR In Vivo Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter's Syndrome | Elisa Ten Hacken, PhD | 11:30 a.m., Channel 9 |
| <i>Scientific Program:</i> Precision Medicine Approaches to Leukemia Predisposition in Bone Marrow Failure Germline and Somatic Genomics in Ribosomopathies | R. Coleman Lindsley, MD, PhD | 11:30 a.m., Channel 6 |
| 667: Restoring NK Cell Activities in Multiple Myeloma with IL-15 Receptor Agonist NKTR-255 | Rafael Alonso Fernández | 12:00 p.m., Channel 11 |
| 656: Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study | Jacqueline S. Garcia, MD | 12:15 p.m., Channel 15 |
| <i>Education Program:</i> Informed Consent for Genetic Testing in Hematology | Jonathan M. Marron, MD, MPH, Dana-Farber/Boston Children's | 1:30 p.m., Channel 22 |

Monday, December 7, 2020



Dana-Farber
Cancer Institute

Oral Presentations at 2020 ASH Annual Meeting

Note: all times listed are Pacific Time

| Presentation | Speaker | Time/Channel |
|---|--|-----------------------|
| 700: Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) | Caron Jacobson, MD, MMSc | 1:30 p.m., Channel 7 |
| 721: Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma | Mehmet K. Samur, PhD | 2:00 p.m., Channel 11 |
| 744: Pre-Diagnostic and Cancer-Associated Depression and Anxiety Among Patients with Hematologic Malignancies in the United States | Thomas M. Kuczmariski, MD, Brigham and Women's Hospital | 2:00 p.m., Channel 3 |